Ertugliflozin

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 357 publications

Correction to: Ertugliflozin improves animal behaviours associated with oxidative stress and inflammation in a BTBR T + Itpr3tf/J mouse model of autism.

Correction to: Ertugliflozin improves animal behaviours associated with oxidative stress and inflammation in a BTBR T + Itpr3tf/J mouse model of autism.

Journal: Brain communications
Published: June 08, 2026

Assessing the Equitable Use of Formulary Drug Tier Systems: Consequences for Geriatric Patient Population Access and Accessible Medication.

Assessing the Equitable Use of Formulary Drug Tier Systems: Consequences for Geriatric Patient Population Access and Accessible Medication.

Journal: Innovations in pharmacy
Published: June 08, 2026

Factors That Influence Blood Pressure Changes With the Use of Sodium-Glucose Cotransporter 2 Inhibitors in People With Type 2 Diabetes.

Factors That Influence Blood Pressure Changes With the Use of Sodium-Glucose Cotransporter 2 Inhibitors in People With Type 2 Diabetes.

Journal: Pharmacotherapy
Published: March 20, 2026

Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.

Effect of anti-tuberculosis drugs on the pharmacokinetics and pharmacodynamics of novel antidiabetic drugs: A scoping review.

Journal: Pulmonology
Published: March 10, 2026

Ertugliflozin decreases the insulin spike in non-insulin dysregulated standardbred horses following intra-articular triamcinolone administration.

Ertugliflozin decreases the insulin spike in non-insulin dysregulated standardbred horses following intra-articular triamcinolone administration.

Journal: Domestic animal endocrinology
Published: January 29, 2026

Pharmacokinetic interactions between three SGLT2 inhibitors and telmisartan: A focus on empagliflozin, ertugliflozin, and henagliflozin.

Pharmacokinetic interactions between three SGLT2 inhibitors and telmisartan: A focus on empagliflozin, ertugliflozin, and henagliflozin.

Journal: PloS one
Published: January 13, 2026

Therapeutic intensity and patient-reported outcomes among heart failure patients in a pharmacist-led medication therapy adherence clinic program in Malaysia.

Therapeutic intensity and patient-reported outcomes among heart failure patients in a pharmacist-led medication therapy adherence clinic program in Malaysia.

Journal: Frontiers in health services
Published: January 09, 2026

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications.

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications.

Journal: Drugs in context
Published: January 07, 2026

Placental transfer characteristics and functional impact of SGLT2 inhibitors in human experimental models.

Placental transfer characteristics and functional impact of SGLT2 inhibitors in human experimental models.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 02, 2025

Noninsulin drugs for type 2 diabetes.

Noninsulin drugs for type 2 diabetes.

Journal: The Medical letter on drugs and therapeutics
Published: November 19, 2025

Comparison chart: Sodium-glucose cotransporter 2 (SGLT2) inhibitors.

Comparison chart: Sodium-glucose cotransporter 2 (SGLT2) inhibitors.

Journal: The Medical letter on drugs and therapeutics
Published: November 19, 2025

Impact of diabetes on the effects of SGLT2 inhibitors on kidney outcomes: An updated drug/dose-dependent meta-analysis.

Impact of diabetes on the effects of SGLT2 inhibitors on kidney outcomes: An updated drug/dose-dependent meta-analysis.

Journal: Clinical nephrology
Published: November 14, 2025
Showing 1-12 of 357

Last Updated: 06/30/2026